Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. more
Time Frame | RVMD | Sector | S&P500 |
---|---|---|---|
1-Week Return | 4.62% | 2.44% | 2.57% |
1-Month Return | -22.75% | -4.49% | 0.09% |
3-Month Return | 3.26% | -8.82% | 4.76% |
6-Month Return | 17.88% | -4.46% | 9.89% |
1-Year Return | 56.71% | 3.16% | 26.47% |
3-Year Return | 70.07% | -0.83% | 25.98% |
5-Year Return | 56.71% | 35.65% | 86.34% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 50.04M | 42.98M | 29.39M | 35.38M | 11.58M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":85.9,"profit":true},{"date":"2021-12-31","value":58.73,"profit":true},{"date":"2022-12-31","value":70.7,"profit":true},{"date":"2023-12-31","value":23.14,"profit":true}] |
Cost of Revenue | 91.75M | 132.25M | 7.33M | 9.66M | 411.24M | [{"date":"2019-12-31","value":22.31,"profit":true},{"date":"2020-12-31","value":32.16,"profit":true},{"date":"2021-12-31","value":1.78,"profit":true},{"date":"2022-12-31","value":2.35,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (41.71M) | (89.27M) | 22.06M | 25.72M | 11.58M | [{"date":"2019-12-31","value":-162.16,"profit":false},{"date":"2020-12-31","value":-347.03,"profit":false},{"date":"2021-12-31","value":85.75,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":45.02,"profit":true}] |
Gross Margin | (83.36%) | (207.68%) | 75.05% | 72.71% | 100.00% | [{"date":"2019-12-31","value":-83.36,"profit":false},{"date":"2020-12-31","value":-207.68,"profit":false},{"date":"2021-12-31","value":75.05,"profit":true},{"date":"2022-12-31","value":72.71,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 104.16M | 153.68M | 217.40M | 293.66M | 498.76M | [{"date":"2019-12-31","value":20.88,"profit":true},{"date":"2020-12-31","value":30.81,"profit":true},{"date":"2021-12-31","value":43.59,"profit":true},{"date":"2022-12-31","value":58.88,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (54.12M) | (110.70M) | (188.01M) | (258.28M) | (487.19M) | [{"date":"2019-12-31","value":-5412000000,"profit":false},{"date":"2020-12-31","value":-11069700000,"profit":false},{"date":"2021-12-31","value":-18800800000,"profit":false},{"date":"2022-12-31","value":-25827900000,"profit":false},{"date":"2023-12-31","value":-48718500000,"profit":false}] |
Total Non-Operating Income/Expense | 4.17M | 4.33M | 1.83M | 18.31M | 94.47M | [{"date":"2019-12-31","value":4.41,"profit":true},{"date":"2020-12-31","value":4.59,"profit":true},{"date":"2021-12-31","value":1.94,"profit":true},{"date":"2022-12-31","value":19.38,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (52.04M) | (108.53M) | (187.09M) | (249.13M) | (439.89M) | [{"date":"2019-12-31","value":-5203700000,"profit":false},{"date":"2020-12-31","value":-10853000000,"profit":false},{"date":"2021-12-31","value":-18709100000,"profit":false},{"date":"2022-12-31","value":-24912500000,"profit":false},{"date":"2023-12-31","value":-43989100000,"profit":false}] |
Income Taxes | (4.37M) | (371.00K) | (7.32M) | (420.00K) | (3.52M) | [{"date":"2019-12-31","value":-437300000,"profit":false},{"date":"2020-12-31","value":-37100000,"profit":false},{"date":"2021-12-31","value":-732000000,"profit":false},{"date":"2022-12-31","value":-42000000,"profit":false},{"date":"2023-12-31","value":-352400000,"profit":false}] |
Income After Taxes | (47.66M) | (108.16M) | (179.77M) | (248.71M) | (436.37M) | [{"date":"2019-12-31","value":-4766400000,"profit":false},{"date":"2020-12-31","value":-10815900000,"profit":false},{"date":"2021-12-31","value":-17977100000,"profit":false},{"date":"2022-12-31","value":-24870500000,"profit":false},{"date":"2023-12-31","value":-43636700000,"profit":false}] |
Income From Continuous Operations | (47.66M) | (108.16M) | (187.09M) | (248.71M) | (436.37M) | [{"date":"2019-12-31","value":-4766400000,"profit":false},{"date":"2020-12-31","value":-10815900000,"profit":false},{"date":"2021-12-31","value":-18709100000,"profit":false},{"date":"2022-12-31","value":-24870500000,"profit":false},{"date":"2023-12-31","value":-43636700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (47.66M) | (108.16M) | (179.77M) | (248.71M) | (436.37M) | [{"date":"2019-12-31","value":-4766400000,"profit":false},{"date":"2020-12-31","value":-10815900000,"profit":false},{"date":"2021-12-31","value":-17977100000,"profit":false},{"date":"2022-12-31","value":-24870500000,"profit":false},{"date":"2023-12-31","value":-43636700000,"profit":false}] |
EPS (Diluted) | (6.89) | (2.14) | (2.56) | (3.10) | (3.77) | [{"date":"2019-12-31","value":-689,"profit":false},{"date":"2020-12-31","value":-214,"profit":false},{"date":"2021-12-31","value":-256,"profit":false},{"date":"2022-12-31","value":-310,"profit":false},{"date":"2023-12-31","value":-377,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RVMD | |
---|---|
Cash Ratio | 13.98 |
Current Ratio | 14.24 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RVMD | |
---|---|
ROA (LTM) | -28.56% |
ROE (LTM) | -47.18% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RVMD | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.11 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.89 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RVMD | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 11055.32 |
P/B | 5.24 |
Price/FCF | NM |
EV/R | 9083.96 |
EV/Ebitda | NM |
Revolution Medicines Inc (RVMD) share price today is $44.085
Yes, Indians can buy shares of Revolution Medicines Inc (RVMD) on Vested. To buy Revolution Medicines Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RVMD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Revolution Medicines Inc (RVMD) via the Vested app. You can start investing in Revolution Medicines Inc (RVMD) with a minimum investment of $1.
You can invest in shares of Revolution Medicines Inc (RVMD) via Vested in three simple steps:
The 52-week high price of Revolution Medicines Inc (RVMD) is $62.4. The 52-week low price of Revolution Medicines Inc (RVMD) is $25.93.
The price-to-earnings (P/E) ratio of Revolution Medicines Inc (RVMD) is
The price-to-book (P/B) ratio of Revolution Medicines Inc (RVMD) is 5.24
The dividend yield of Revolution Medicines Inc (RVMD) is 0.00%
The market capitalization of Revolution Medicines Inc (RVMD) is $8.20B
The stock symbol (or ticker) of Revolution Medicines Inc is RVMD